Sage Therapeutics, Inc. is a biopharmaceutical company. The Company has developed the two FDA-approved treatments indicated for postpartum depression and is advancing a robust pipeline to target unmet needs in brain health. The Company is targeting diseases and disorders of the brain across its clinical development and earlier stage pipeline. Its product ZURZUVAE is for the treatment of postpartum depression (PPD) in adults. ZURZUVAE is a neuroactive steroid that is a positive allosteric modulator of GABA receptors, targeting both synaptic and extra synaptic GABA receptors. Its product ZULRESSO (brexanolone) CIV injection is for the treatment of PPD in individuals 15 years old and older. It is also developing a portfolio of other novel compounds that target GABA receptors, including SAGE-324, which is a novel GABAA receptor positive allosteric modulator intended for chronic oral dosing. Its second area of focus for development is novel compounds that target the NMDA receptor.

Employees

353

Sector

Biotechnology & Medical Research

Calendar

02-17 - Q4 2025 Earnings Release (Projected)

More about the company

Income Statement and Estimates

More financial data

Market Closed - Nasdaq Other stock markets 21:00:00 30/07/2025 BST			5-day change	1st Jan Change
8.680 ^USD	-0.23%		-.--%	-

31/07/25	Supernus Pharmaceuticals Completes Sage Therapeutics Acquisition	MT
31/07/25	Sage Therapeutics, Inc. Announces Management Changes	CI

Capitalization	544M 463M 429M 404M 751M 49.47B 806M 4.95B 1.96B 23.52B 2.04B 2B 85.84B	P/E ratio 2023	-2.39x	P/E ratio 2024	-0.82x
Enterprise value	50.98M 43.45M 40.26M 37.86M 70.48M 4.64B 75.6M 465M 184M 2.21B 191M 187M 8.05B	EV / Sales 2023	6.4x	EV / Sales 2024	-3.89x
Free-Float	87.64%	Yield 2023 *	-	Yield 2024	-

31/07/25	Supernus Pharmaceuticals Completes Sage Therapeutics Acquisition	MT
31/07/25	Sage Therapeutics, Inc. Announces Management Changes	CI
31/07/25	Supernus Pharmaceuticals completes acquisition of Sage Therapeutics	RE
31/07/25	Sage Therapeutics, Inc.(NasdaqGM:SAGE) dropped from S&P Global BMI Index	CI
31/07/25	Sage Therapeutics, Inc.(NasdaqGM:SAGE) dropped from S&P TMI Index	CI
30/07/25	Sage Therapeutics, Inc.(NasdaqGM:SAGE) dropped from NASDAQ Composite Index	CI
30/07/25	Saphire, Inc completed the acquisition of Sage Therapeutics, Inc..	CI
30/07/25	Sage Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
30/07/25	SAGE Therapeutics Q2 revenue rises sequentially	RE
30/07/25	Earnings Flash (SAGE) Sage Therapeutics, Inc. Reports Q2 Revenue $31.7M, vs. FactSet Est of $16.8M	MT
29/07/25	Sage Therapeutics, Inc.(NasdaqGM:SAGE) dropped from Russell Small Cap Comp Value Index	CI
29/07/25	Sage Therapeutics, Inc.(NasdaqGM:SAGE) dropped from Russell Small Cap Comp Value Benchmark	CI
29/07/25	Sage Therapeutics, Inc.(NasdaqGM:SAGE) dropped from Russell 3000E Value Benchmark	CI

08/07/25	Scotiabank Downgrades SAGE Therapeutics to Sector Perform From Sector Outperform, Adjusts Price Target to $9.20 From $12	MT
17/06/25	Piper Sandler Downgrades SAGE Therapeutics to Neutral From Overweight, Adjusts Price Target to $8.50 From $9	MT
16/06/25	Truist Securities Adjusts SAGE Therapeutics Price Target to $9 From $8, Maintains Hold Rating	MT
16/06/25	Wedbush Adjusts PT on SAGE Therapeutics to $8.50 From $6 on Heels of Announced Sale to Supernus; Maintains Neutral	MT
03/04/25	RBC Raises Price Target on SAGE Therapeutics to $7 From $6, Keeps Sector Perform, Speculative Risk	MT

Sage Therapeutics, Inc. Share Price

Equities

SAGE

US78667J1088

Biotechnology & Medical Research

Valuation: Sage Therapeutics, Inc.

Chart: Sage Therapeutics, Inc.

Latest news: Sage Therapeutics, Inc.

Last Transcript: Sage Therapeutics, Inc.

Analysts' recommendations: Sage Therapeutics, Inc.

Press Releases: Sage Therapeutics, Inc.

News in other languages: Sage Therapeutics, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Sage Therapeutics, Inc.

Bio Therapeutic Drugs

Financials

Company Profile

Income Statement and Estimates

31/07/25	Sage Therapeutics : Leonteq Securities AG - Übernahme/Fusion/Spin-off (Sponsored Segment)
16/06/25	Wall Street hoger gesloten na handreiking Iran
13/01/25	Hogere rentes duwen Nasdaq opnieuw in het rood
13/01/25	Aktien New York: Techs bleiben schwach - Fantasie für Zinssenkungen schwindet
13/01/25	En direct des marchés : Elis et BioMérieux à l'achat, McPhy en PLS, UBS trop grosse

1 year	6.14	9.36
3 years	4.62	59.99
5 years	4.62	91.75
10 years	4.62	195.97

Manager	Title	Age	Since
Christopher Benecchi DFI	Director of Finance/CFO	-	31/10/2024
Jack Khattar PSD	President	64	30/07/2025
Mike Quirk CTO	Chief Tech/Sci/R&D Officer	-	08/10/2023

Director	Title	Age	Since
Jessica Federer BRD	Director/Board Member	-	14/03/2023
Jack Khattar BRD	Director/Board Member	64	30/07/2025

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
SAGE THERAPEUTICS, INC.	-0.23%	-.--%	+22.60%	-79.61%	544M
ARGENX SE	+1.84%	-1.61%	+8.10%	+92.91%	49.24B
WUXI APPTEC CO., LTD.	-2.86%	-4.91%	+77.51%	+2.01%	42.5B
INSMED INCORPORATED	+1.29%	-0.13%	+125.50%	+683.09%	34.87B
BIONTECH SE	-3.16%	-1.52%	-5.69%	-26.07%	26.49B
WUXI BIOLOGICS (CAYMAN) INC.	+2.59%	-4.80%	+109.23%	-46.67%	19.66B
GENMAB A/S	-2.20%	-6.90%	+32.32%	-27.08%	19.33B
AKESO, INC.	-3.49%	-7.86%	+93.53%	+125.15%	13.89B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-3.93%	-9.01%	+166.75%	-	13.23B
SUMMIT THERAPEUTICS INC.	-5.75%	-4.46%	-15.61%	+265.83%	12.38B
Average	-1.58%	-3.56%	+61.42%	+109.95%	23.21B
Weighted average by Cap.	-1.00%	-3.22%	+60.37%	+143.15%

	2023	2024
Net sales	86.46M 73.69M 68.27M 64.21M 120M 7.87B 128M 788M 311M 3.74B 324M 318M 13.65B	41.24M 35.15M 32.57M 30.63M 57.02M 3.75B 61.16M 376M 149M 1.78B 155M 151M 6.51B
Net income	-541M -462M -428M -402M -749M -49.28B -803M -4.94B -1.95B -23.43B -2.03B -1.99B -85.52B	-401M -341M -316M -298M -554M -36.47B -594M -3.65B -1.44B -17.34B -1.5B -1.47B -63.28B
Net Debt	-748M -638M -591M -556M -1.03B -68.08B -1.11B -6.82B -2.69B -32.37B -2.81B -2.75B -118B	-493M -420M -389M -366M -681M -44.83B -730M -4.49B -1.77B -21.32B -1.85B -1.81B -77.79B

1 day	-0.23%
6 months	-4.72%